Reportlinker Adds Triple Analysis: Pancreatic Cancer, Angiogenesis and Peptides
NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Triple Analysis: Pancreatic Cancer, Angiogenesis and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 213 pancreatic cancer drugs within the portfolio of 137 investigators, from Ceased to Marketed. This report part extensively analyses 171 identified targets of pancreatic cancer drugs, organized into 142 drug target profiles, and assesses them in pancreatic cancer.
This part is based on the following publication:
Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?
Part II: Angiogenesis
The angiogenesis report part comprises defined and up to date development strategies for 239 drugs affecting angiogenesis in oncology within the portfolio of 148 investigators, from Preclinical to Marketed. This report part extensively analyses 174 identified targets of angiogenesis affecting drugs, organized into 167 drug target strategies, and assesses them in 64 different cancer indications.
This part is based on the following publication:
Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline
Part III: Peptides
The peptide report part comprises defined and up to date development strategies for 145 cancer peptide drugs within the portfolio of 103 investigators, from Ceased to Marketed. This report part extensively analyses 125 identified targets of peptide drugs, organized into 103 drug target strategies, and assesses them in 52 different cancer indications.
This part is based on the following publication:
Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:
* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
* Supporting development of integrative molecule, pathway and disease area strategies
* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.
Key Topics Covered:
Part I: Pancreatic Cancer
5.1 The Scope of this Report 24
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (171 Drug Targets) 28
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Strategies Identified in the Pancreatic Cancer Therapeutic Pipeline? (142 Drug Target Strategies and 213 Drugs) 333
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 374
9 Pipeline and Portfolio Planning: Competitive Benchmarking of Pancreatic Cancer Therapeutic Pipeline by Investigator (137 Investigators) 408-599
11 Drug Index 601
12 Company Index 606
Figures: Includes 5 Figures
Tables: Includes 193 Tables
Total Number of Pages: 610
Part II: Angiogenesis
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (174 Drug Targets) 39-366
7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167 Drug Target Strategies and 239 Drugs) 367-437
8 Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies) 438-485
9 Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology (64 Cancer Indications) 486-643
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148 Investigators) 644-1211
10 Disclaimer 1212
11 Drug Index 1213
12 Company Index 1221
Figures: Includes 7 Figures
Tables: Includes 300 Tables
Total Number of Pages: 1227
Part III: Peptides
5.1 The Scope of this Report 24
5.2 The Competitive Advantage and Disadvantage of Peptide Drugs 26
6 Consider the Therapeutic Peptide Target for the Highest Therapeutic Outcome and Return on Investment (125 Drug Targets) 29-219
7 Emerging New Products to Established Ones: Drug Target Strategies of Peptides by their Highest Stage of Development in Oncology (103 Drug Target Strategies and 145 Peptide Drugs) 220-246
8 Selecting Cancer Indications for Peptide Drugs (52 Cancer Indications) 247-300
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Peptide Drug Pipeline in Oncology by Investigator (103 Investigators) 301-586
10 Disclaimer 588
11 Drug Index 589
12 Company Index 593
Figures: Includes 4 Figures
Tables: Includes 192 Tables
Total Number of Pages: 596
To order this report:
Drug Discovery and Development Industry: Triple Analysis: Pancreatic Cancer, Angiogenesis and Peptides
Drug Discovery and Development Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article